Ranibizumab

Details

Files

Generic Name:

Ranibizumab

Project Status:

Complete

Therapeutic Area:

Macular degeneration, age-related

Manufacturer:

Novartis Pharmaceuticals Inc.

Brand Name:

Lucentis

Project Line:

Reimbursement Review

Project Number:

SR0098-000

Submission Type:

Initial

Indications:

Macular degeneration, age-related

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

March 27, 2008

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Summary of CEDAC Discussion View PDF

Overview of CDR Reports View PDF

Plain Language Recommendation View PDF

Last Updated : July 12, 2007